Establishing a benchmark for both cognitive and functional aspects of brain health has several important applications within the field of neurology, including the ability to provide earlier diagnoses for Alzheimer’s and other neurological diseases. Baseline testing also has critical applications for younger athletes. It helps establish an individual’s unique benchmark for brain function to better understand when they can return to sport, work, or school in the event of a concussion.
Below we detail the importance of baseline testing for younger patients and athletes, limitations of traditional baseline assessments and tools, and how to improve assessment of neurocognitive function.
Baseline testing for younger patients, whether it’s for neurological disease or concussions, allows doctors and their patients to make informed decisions. Baseline testing for athletes assesses brain function, such as verbal and visual memory, cognitive processing speed, and reaction time. Standard assessments used to detect signs of neurological diseases traditionally look primarily at a narrow range of neurocognitive functions, including memory, orientation, attention, visuospatial abilities, language, learning, and judgment.
While cognitive impairments may be present after a head injury, concussion is a functional brain injury, meaning a scan or simple cognitive test is not sufficient to determine if both cognitive and functional impairments are no longer present before returning to sport. Similarly, many neurological diseases present with both cognitive and functional impairments, yet most testing methods place a narrow focus on specific, symptom-oriented cognition testing. While tools exist to assess functional impairments in neurological diseases, they lack the sensitivity and specificity required to detect small changes in functional brain health.
Baseline testing for younger patients, even as young as 30, is crucial for early diagnosis of a wide range of neurological diseases, such as Alzheimer’s disease, Parkinson’s disease, Lewy body dementia, and Huntington’s Disease. With the rapidly growing prevalence of Alzheimer’s and other neurological diseases, there is a clear need for earlier diagnosis to provide better patient outcomes. This is particularly important as new therapies and treatments emerge, as many neurological diseases are more treatable in the earlier, less severe stages. Early and regular testing of brain function can help detect small changes in brain function even before clinical onset, paving the way for the early detection of neurological diseases.
Traditional tools for detecting neurological disease only assess a few neurocognitive domains and thus only scratch the surface for understanding cognitive and functional brain health as it relates to a patient’s ability to complete Activities of Daily Living (ADLs). Take the Mini-Mental State Exam (MMSE) and Montreal Cognitive Assessment (MoCA), for example. Simple memory tests do not evoke a neurocognitive state representative of ADLs and thus may not be ecologically valid. The narrow nature of traditional assessments and the lack of data granularity may result in a missed opportunity for early detection. Such assessments may not have the specificity and data granularity to detect small cognitive or functional changes that could provide an early indication of the development of neurological disease.
While functional assessments, such as the Katz ADL and Lawton-Brody Instrumental ADL, can be used to assess functional impairments, they may not be sensitive to small, incremental, intra-individual changes.
Baseline testing for younger patients, particularly for athletes, is typically conducted by a healthcare provider to provide a pre-season assessment of an athlete’s brain function. This provides their unique baseline to support healthcare providers in interpreting scores of post-concussion tests. It can further be used to determine when an athlete has recovered from the concussion and is fit to return to sport. In other words, when an athlete’s post-concussion brain function scores align with their pre-season baseline scores, providers may clear them to return to sport with minimal risks.
Baseline concussion tests, such as the Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT), are typically computer-based assessment tools that take approximately 20 minutes to complete and must be interpreted by a healthcare professional. While such assessments may provide a good indication of overall cognitive function, they may not provide a comprehensive analysis of cognitive and functional abilities.
To adequately understand neurocognitive function for neurological disease or post-concussion brain function, a more comprehensive approach that addresses an individual’s ability to complete complex ADLs can provide a significantly greater degree of insight into cognitive and functional aspects of brain health.
Altoida is developing a Precision Neurology platform and app-based medical device to measure and monitor brain health as accurately and effectively as possible. By engaging in a 10-minute series of augmented reality and motor activities designed to simulate complex ADLs, Altoida transforms any smartphone or tablet into the world’s most powerful medical device to assess neurocognitive function.
Altoida’s device collects and analyzes nearly 800 cognitive and functional digital biomarkers from smartphone or tablet sensors while users complete digital activities. By measuring both cognitive and functional digital biomarkers across 13 neurocognitive domains, Altoida’s device may be a valuable tool in baseline testing for younger patients and athletes as well as to measure and monitor minute changes in neurocognitive function over time, enabling a comprehensive understanding of brain health.
To learn more about how Altoida’s Precision Neurology device will be used for baseline testing for younger patients, contact us today.